Raaj Medisafe India Limited

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, VOEPL.BO has a market cap of 8.8B. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while VOEPL.BO trades at ₹392.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas VOEPL.BO's P/E ratio is 115.99. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to VOEPL.BO's ROE of +0.06%. Regarding short-term risk, RAAJMEDI.BO is less volatile compared to VOEPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check VOEPL.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, PREVEST.BO has a market cap of 5.8B. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while PREVEST.BO trades at ₹466.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas PREVEST.BO's P/E ratio is 29.38. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to PREVEST.BO's ROE of +0.19%. Regarding short-term risk, RAAJMEDI.BO is less volatile compared to PREVEST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check PREVEST.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, HSIL.BO has a market cap of 3.1B. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while HSIL.BO trades at ₹296.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas HSIL.BO's P/E ratio is 40.86. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to HSIL.BO's ROE of +0.11%. Regarding short-term risk, RAAJMEDI.BO is less volatile compared to HSIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check HSIL.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, CHOKSI.BO has a market cap of 892.8M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while CHOKSI.BO trades at ₹159.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas CHOKSI.BO's P/E ratio is 26.72. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to CHOKSI.BO's ROE of +0.16%. Regarding short-term risk, RAAJMEDI.BO is less volatile compared to CHOKSI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check CHOKSI.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, KRETTOSYS.BO has a market cap of 548.6M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while KRETTOSYS.BO trades at ₹0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas KRETTOSYS.BO's P/E ratio is 81.00. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to KRETTOSYS.BO's ROE of +0.02%. Regarding short-term risk, RAAJMEDI.BO is less volatile compared to KRETTOSYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check KRETTOSYS.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, SHREEPAC.BO has a market cap of 477.7M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while SHREEPAC.BO trades at ₹134.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas SHREEPAC.BO's P/E ratio is 20.19. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to SHREEPAC.BO's ROE of +0.18%. Regarding short-term risk, RAAJMEDI.BO is less volatile compared to SHREEPAC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check SHREEPAC.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, KMSMEDI.BO has a market cap of 397.6M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while KMSMEDI.BO trades at ₹126.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas KMSMEDI.BO's P/E ratio is N/A. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to KMSMEDI.BO's ROE of +0.08%. Regarding short-term risk, RAAJMEDI.BO is more volatile compared to KMSMEDI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check KMSMEDI.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, CSURGSU.BO has a market cap of 345.3M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while CSURGSU.BO trades at ₹94.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas CSURGSU.BO's P/E ratio is -17.82. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to CSURGSU.BO's ROE of -0.03%. Regarding short-term risk, RAAJMEDI.BO is less volatile compared to CSURGSU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check CSURGSU.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, GKB.BO has a market cap of 314.1M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while GKB.BO trades at ₹60.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas GKB.BO's P/E ratio is -6.28. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to GKB.BO's ROE of -0.05%. Regarding short-term risk, RAAJMEDI.BO is less volatile compared to GKB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check GKB.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, ADESHWAR.BO has a market cap of 303.1M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while ADESHWAR.BO trades at ₹18.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas ADESHWAR.BO's P/E ratio is 16.03. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to ADESHWAR.BO's ROE of +0.04%. Regarding short-term risk, RAAJMEDI.BO is more volatile compared to ADESHWAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check ADESHWAR.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, SDL.BO has a market cap of 190.8M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while SDL.BO trades at ₹34.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas SDL.BO's P/E ratio is -9.12. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to SDL.BO's ROE of +0.38%. Regarding short-term risk, RAAJMEDI.BO is more volatile compared to SDL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check SDL.BO's competition here

RAAJMEDI.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAAJMEDI.BO stands at 1.1B. In comparison, NOVATEOR.BO has a market cap of 188.9M. Regarding current trading prices, RAAJMEDI.BO is priced at ₹85.99, while NOVATEOR.BO trades at ₹31.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAAJMEDI.BO currently has a P/E ratio of 14.80, whereas NOVATEOR.BO's P/E ratio is 520.17. In terms of profitability, RAAJMEDI.BO's ROE is +0.29%, compared to NOVATEOR.BO's ROE of N/A. Regarding short-term risk, RAAJMEDI.BO is more volatile compared to NOVATEOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for RAAJMEDI.BO.Check NOVATEOR.BO's competition here